LIBREXIA-ACS (Janssen — Milvexian)
Phase 3 — Acute Coronary Syndrome
Indication: Acute Coronary Syndrome
Sponsor: Janssen · Janssen 70033093ACS3003 · NCT05754957
About this study
Pivotal Phase 3 LIBREXIA-ACS study evaluating a novel antithrombotic strategy in patients following an acute coronary syndrome event. Recently completed.
To test whether a novel antithrombotic strategy reduces cardiovascular events after a recent acute coronary syndrome.
Study details
- Sponsor
- Janssen
- Protocol
- Janssen 70033093ACS3003
- Phase
- Phase 3
- Indication
- Phase 3 — Acute Coronary Syndrome
- Status
- Completed
High-level eligibility
- Adults with recent ACS event
- Clinically stable for randomization
- On standard-of-care therapy
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit at amavita Heart and Vascular Health®.
For patients
Read: Acute Coronary Syndrome Clinical Trials — A Patient's Guide →
I'm a sponsor / CRO →
Discuss enrollment, capacity, and operational fit.
I might be eligible — call (786) 703-5941 →
Free, no-obligation pre-screen in English / Spanish / Haitian Creole.
Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.